The Vascular Covered Stent is deployed from a delivery system that provides controlled stent release. Credit: PRNewswire/BD (Becton, Dickinson and Company).

Becton, Dickinson and Company (BD) has enrolled the first subject in the investigational device exemption study, AGILITY, using its Vascular Covered Stent to expand treatment options for peripheral arterial disease (PAD).

The study will evaluate the safety and effectiveness of the BD Vascular Covered Stent, a low-profile, self-expanding, polytetrafluoroethylene encapsulated nitinol implant.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The AGILITY clinical study is a global, prospective, multi-centre, single-arm, non-randomised investigation.

It will involve 315 patients at up to 40 trial sites across the US, Europe, New Zealand and Australia. Patients will be followed up at various points post-treatment, from one month up to 36 months.

For the trial, the company enrolled the first patient at Trinity Medical Center in Bettendorf, Iowa, US.

Cardiovascular Medicine interventional cardiologist; Midwest Cardiovascular Research Foundation founder and president; and University of Iowa Adjunct professor of Medicine Dr Nicolas Shammas led the enrolment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Vascular Covered Stent is deployed from a delivery system designed for controlled stent release.

Cleveland Clinic Department of Vascular Surgery chairman and the AGILITY study national principal investigator Dr Sean Lyden said: “When we’re addressing advanced PAD, a self-expanding covered stent can play an important role.

“We need a stent that can track the lesion, apposes the vessel wall and ultimately provides long-term durability. We’re excited to see how this technology performs.”

BD Peripheral Intervention vice-president and general manager Tim Hug said: “There continues to be significant unmet needs in the treatment of PAD patients.

“We are excited to have initiated this study and evaluate the treatment benefits of this potentially differentiated technology.

“This stent could give interventionalists an important new solution in the fight against PAD, expand our portfolio and enable us to better serve our customers and the patients they treat.”

Recently, BD partnered with Camtech Health in Singapore to introduce a self-collection human papillomavirus (HPV) test for women to use at home.